LINC00342 promotes thyroid carcinoma progression by targeting miR-384/CHMP5 pathway

Abstract Thyroid carcinoma (THCA) is the most common thyroid malignancy and accounts for 1% of overall malignant tumors. Long intergenic non-protein coding RNA 342 (LINC00342) has been validated to be a regulator in non-small cell lung cancer (NSCLC). However, the biological role of LINC00342 in THCA has not been reported or discussed yet. Therefore, the present study focused on the role of LINC00342 and its mechanism in THCA. Firstly, real-time quantitative polymerase chain reaction (RT-qPCR) was conducted for detecting LINC00342 expression in THCA and the outcomes disclosed that LINC00342 had a high expression in THCA tissues and cells. Besides, functional assays reflected that LINC00342 silence inhibited THCA progression by anti-proliferation, anti-migration/invasion and pro-apoptosis as well as blocking epithelial-mesenchymal transition (EMT). Next, through RNA immunoprecipitation (RIP), RNA pull down and luciferase reporter assays, we confirmed that LINC00342 and charged multivesicular body protein 5 (CHMP5) could bind to miR-384. Further, the expression of CHMP5 was declined with miR-384 up-regulation or LINC00342 down-regulation. Finally, rescue experiments revealed that CHMP5 upregulation reversed LINC00342 knockdown-mediated effects on THCA cells. All data showed that LINC00342 promoted THCA progression by absorbing miR-384 to upregulate CHMP5 expression. These findings proved that LINC00342 might be a promising target for THCA treatment.